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ABSTRACT
Weight loss improves metabolic abnormalities and reduces cardiovascu-
lar risk in obese hypertensive patients. To evaluate the impact of a sus-
tained weight loss on coronary risk, 181 hypertensive patients with meta-
bolic syndrome underwent to orlistat therapy, 120 mg, t.i.d., plus diet for
36 weeks. During therapy, Framingham risk scores (FRS) were calculated
for determination of coronary heart disease risk in ten years. Body mass
index decreased from 35.0 ± 4.2 to 32.6 ± 4.5 kg/m2 (p< 0.0001) and waist
circumference from 108.1 ± 10.1 to 100.5 ± 11.1 cm (p< 0.0001), at the
end of the study period (week 36). Systolic and diastolic blood pressure
showed reductions after the two first weeks, which were maintained up
to the end of the study. A clear shift to the left in FRS distribution curve
occurred at the end of the study, compared to baseline, indicating a
reduction in coronary risk. Over all patients at risk, 49.2% moved to a
lower risk category. A weight loss ≥ 5% occurred in 64.6% of all patients,
associated with improvement in glucose metabolism. Among those with
abnormal glucose metabolism, 38 out 53 patients (71.7%) improved their
glucose tolerance (p< 0.0005). In conclusion, long-term orlistat therapy
helps to reduce and maintain a lower body weight, decreasing risk of
coronary disease and improving glucose metabolism, thus protecting
against type 2 diabetes. (Arq Bras Endocrinol Metab 2006;50/2:368-376)
Keywords: Central obesity; Orlistat; Weight reduction; Cardiovascular risk;
Framingham risk score
RESUMO
Avaliação do Risco Cardiovascular em Pacientes Obesos Hipertensos
com Síndrome Metabólica: Estudo ARCOS.
A perda de peso melhora as anormalidades metabólicas e reduz o risco
cardiovascular em pacientes obesos hipertensos. Com o objetivo de
avaliar o impacto da perda de peso mantida sobre o risco coronariano,
submetemos 181 pacientes hipertensos com síndrome metabólica à te-
rapia com orlistat, 120 mg, três vezes ao dia, mais dieta, por um período
de 36 semanas. Durante a terapia, foram calculados os scores de risco
de Framingham (FRS) para a determinação do risco de doença cardía-
ca coronariana em dez anos. Ao final do período de estudo (semana
36), o índice de massa corpóreo diminuiu de 35,0 ± 4,2 para 32,6 ± 4,5
kg/m2 (p< 0,0001) e a circunferência da cintura de 108,1 ± 10,1 para
100,5 ± 11,1 cm (p< 0,0001). As pressões sistólica e diastólica mostraram
reduções após as primeiras duas semanas, que se mantiveram até o
final do estudo. Um deslocamento evidente para a esquerda na curva
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de distribuição do FRS ocorreu no final do estudo, em
comparação com os valores basais, indicando
redução no risco coronariano. Do total de pacientes
em risco, 49,2% passou para uma categoria de risco
menor. Ocorreu perda de peso ≥ 5% em 64,6% de
todos os pacientes, associada com melhora no
metabolismo da glicose. Entre os 53 pacientes com
metabolismo de glicose anormal, 38 (71,7%) melho-
raram sua tolerância à glicose (p< 0,0005). Em con-
clusão, terapia de longa duração com orlistat auxilia
a reduzir e manter mais baixo o peso corpóreo,
reduzindo o risco de doença coronária e melhoran-
do o metabolismo da glicose e protegendo, dessa
maneira, contra o diabetes tipo 2. (Arq Bras
Endocrinol Metab 2006;50/2:368-376)
Descritores: Obesidade central; Orlistat; Redução de
peso; Risco cardiovascular; Score de risco de Fram-
ingham.
HYPERTENSION IS A MAJOR risk factor for all clinicalmanifestations of atherosclerosis in both sexes at
all ages (1). A 36-year follow-up of individuals aged
35–64 years in the Framingham Heart Study showed
that hypertensive patients have an excess risk of coro-
nary heart disease, stroke, peripheral artery disease,
and heart failure compared with patients with normal
blood pressure. Part of the excessive cardiovascular risk
in hypertensive patients is due to the presence of the
metabolic syndrome (2), a cluster of cardiovascular
risk factors closely linked to insulin resistance (3).
Hypertension, dyslipidemia, and glucose intolerance
promote accelerated atherogenesis and correcting
them stabilizes lesions and slows its progression.
Because the burden of metabolic risk factors accompa-
nying hypertension is promoted by weight gain lead-
ing to visceral adiposity and insulin resistance, weight
control is of paramount importance (4-6).
Several studies have shown that weight loss
improves metabolic abnormalities and reduces cardio-
vascular risk in obese hypertensive patients (7-9).
However, weight reduction and the long-term main-
tenance of lower body weight can be difficult to
achieve, and not many obese patients maintain the
short-term weight losses achieved following dietary
restriction (10-12). Pharmacological treatment pro-
moting long-term weight reduction and improving
insulin resistance-related risk factors may benefit many
overweight hypertensive patients at risk of vascular
events. Orlistat acts as an inhibitor of pancreatic, gas-
tric, carboxyl ester lipase, which consequently results
in both, decreased absorption of fat and emission of
unabsorbed cholesterol and triacylglycerols. The
intake of excess dietary fat is one of the leading causes
of obesity, and the above-described systemic effect
should facilitate weight loss in obese subjects. Orlistat
therapy, in conjunction with diet, has been shown to
result in significantly greater weight loss and improve-
ment in risk factors than diet alone among obese
patients at high risk of coronary events (13,14). The
primary objective of this study was to further investi-
gate the impact of long-term body weight reduction
with orlistat on the risk of a coronary event trough the
determination of Framingham Risk Score in hyperten-
sive patients with metabolic syndrome.
PATIENTS AND METHODS
Patients
In this study, 181 patients were included in the inten-
tion to treat (ITT) efficacy analysis population. Eligi-
ble patients were of both sex, 18–70 years of age, with
a BMI > 25 and < 45 kg/m2 and systolic blood pres-
sure ≥ 130 and < 180 mmHg. Patients should also
present at least two of the following factors to charac-
terize the occurrence of metabolic syndrome: waist cir-
cumference in men ≥ 94 cm and women ≥ 80 cm;
plasma triglycerides ≥ 150 and < 400 mg/dl or fasting
plasma glucose ≥ 100 and < 126 mg/dl. Patients on
antihypertensive drugs should be receiving in the past
two months the same dosage of angiotensin conver-
ting enzyme inhibitors, calcium antagonists, angio-
tensin II antagonists, diuretics or beta-blockers.
Exclusion criteria included: total cholesterol ≥
240 mg/dl; diastolic blood pressure ≥ 110 mmHg;
smoking or smoking cessation within past 6 months;
history or presence of significant renal, hepatic, cardiac
or psychiatric disorders; weight loss > 3 kg in the three
months prior to screening, participation in a weight-
loss program (diet or pharmacological) during the past
3 months, previous surgery for obesity; endocrine dis-
orders, excepting patients with impaired glucose toler-
ance or treated hypothyroidism. Patients with acute or
chronic severe diseases possibly affecting the absorp-
tion, metabolism or excretion of the trial medication,
or impairing the evaluation of patient safety and the
outcome of the clinical trial (such as AIDS, tumor dis-
eases, cardiac insufficiency) were also excluded. Drugs
administered for the first time or withdraw during the
past 6 months, which have a significant impact on the
body weight (such as serotoninergically acting drugs,
antidepressants, central adrenergically acting sub-
stances, substances inhibiting digestion and absorp-
tion, thyroid hormones and corticosteroids) were not
allowed. Patients in use of oral hypolipidemic agents,
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oral hypoglycaemic agents or insulin, at any time, were
also excluded. Lactating women, pregnant women or
of childbearing potential not applying a reliable
method of contraception, were not allowed in this
study.
Protocol design
The study was conducted as a multicenter, open-label,
non-comparative in 14 clinical research sites between
2002 and 2003, during 36 weeks with 11 visits with-
in this period. After selection, patients were initially
seen in two visits with two weeks interval and every 4
weeks thereafter. In the first visit patients were sub-
mitted to a complete physical examination, with
weight, height, waist circumference and blood pres-
sure determinations and all other inclusion/exclusion
criteria were checked.
Patients included in the study were instructed
to take a 120 mg capsule of orlistat, orally, together
with the major meals (breakfast, lunch, and dinner)
during 36 weeks. Body weight, body mass index, waist
circumference and blood pressure were recorded at
every study visit. Waist circumference was measured
halfway between the lower rib margin and the iliac
crest in the stand position after a normal expiration.
Systolic and diastolic blood pressures were taken after
a 5-min resting in the sitting position by standard
sphygmomanometry.
Fasting blood glucose and plasma lipid profile,
including total cholesterol, HDL-cholesterol, LDL-
cholesterol and triglycerides, were determinate at visit
1, just before introducing the study medication, at vis-
its 4 (week 8), 6 (week 16), 8 (week 24) and 11 (week
36), at the end of the study. An oral glucose tolerance
test (OGTT) with blood glucose determination before
and 2 hours after an oral glucose load of 75 g was per-
formed before therapy (visit 1) and at the end of the
study period. Total cholesterol (TC), high-density
lipoprotein cholesterol (HDL-C), and triglycerides
(TG) were assessed using an autoanalyser and respec-
tive reagents (Cobas-Miraplus, Roche). Low-density
lipoprotein cholesterol (LDL-C) was calculated by the
Friedewald formula [LDL-C mg/dL= TC in mg/dL –
(TGmg/dL/5 + HDL-C mg/dL)]. Blood glucose
was measured using the glucose-oxidize methodology.
Ninety three patients were submitted to an
abdominal computed tomography (CT), both before
and at the end of the study period. Since CT was per-
formed in more than one clinical research site, to
reduce the variability of the abdominal fat measure-
ment, the thickness of the visceral and subcutaneous
fat was preferred to the measurement of the abdomi-
nal fat areas. Only one axial cut was performed, 5 cm
below the xiphoid process and the thickness of two fat
plans were determined in centimeters. The subcuta-
neous fat was measured, at the middle line, between
the posterior wall of the skin and the anterior wall of
the subjacent muscular plan. The thickness of the vis-
ceral fat was measured between the posterior wall of
the abdominal muscle and the anterior wall of the
aorta. This linear measurement of the visceral fat has
been shown to have a good correlation with the area
of the visceral fat at CT (15).
Framingham risk score (FRS) (16), based on
age, sex, total cholesterol, HDL-cholesterol, blood
pressure values, smoking habits and presence or
absence of diabetes, were calculated at visits 1, 4, 6, 8
and 11 for determination of coronary heart disease
(CHD) risk in ten years.
During the entire 36-week study period, all
patients were prescribed a reduced-calorie diet (~500
kcal/day deficit) containing 30% of calories from fat
and not more than 300 mg of cholesterol per day. Par-
ticipants received dietary counseling every 2 weeks in
the first month and monthly thereafter and were also
encouraged to walk during 30 minutes every day in
addition to their usual physical activity.
The study protocol was approved by the Ethical
Committee of each hospital where the study has been
conducted, and all patients signed an informed consent.
Statistical methods
This was a prospective, multi-centre, open-label study.
The following tests were used: analysis of covariance
(ANCOVA) to investigate the significance of changes
within the whole group and between subgroups over
time. The ANOVA, paired t-test, Wilcoxon signed
rank sum test, Pearson (r) correlation coefficient,
Cochran-Mantel-Haenszel test, and Chi-square tests
were also used. Mean and standard deviation (SD) of
the numerical variables are reported. A two tailed p<
0.05 was considered significant.
RESULTS
The demographic characteristics and the cardiovascu-
lar risk profile of the intention-to-treat (ITT) popula-
tion studied are shown in table 1. This study analyzed
the results of 181 hypertensive patients, the majority
of them female (84%) with age ranging from 25–65
years old and BMI ranging from 27–44 kg/m2. The
presence of hypertension, abdominal obesity associa-
ted with high levels of tryglicerides and/or low levels
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of high-density lipoprotein (HDL)-cholesterol and/or
impaired fasting glycemia characterized the occurrence
of metabolic syndrome in all patients of this popula-
tion. Antihypertensive medication administered dur-
ing the study period included calcium channel block-
ers (35%), diuretics (32.8%), renin-angiotensin block-
ing agents (27.1%) beta blockers (16.9%) and other
agents (6.2%). Fifty nine patients (32.6%) were off
antihypertensive medication.
From the 181 patients included, 155 complet-
ed the treatment (85%). The most common causes of
premature discontinuation were refusal of treatment
(n= 9; 34%), protocol violation (n= 6; 23%) and
adverse event or intercurrent illness (n= 3; 11.5%)
The intention to treat analysis demonstrated
that, during orlistat therapy, as shown in figure 1, body
weight decreased significantly up to week 16, from 89.8
± 13.6 kg to 84.3 ± 13.7 kg (p< 0.0001), with no sig-
nificant changes thereafter, reaching 83.3 ± 14.3 kg at
the end of the study. A mean reduction of 7.3 ± 7.1%
was observed for the whole population. As a conse-
quence, body mass index decreased from the Baseline
value of 35.0 ± 4.2 to 32.6 ± 4.5 kg/m2 (p< 0.0001)
and waist circumference from 108.1 ± 10.1 to 100.5 ±
11.1 cm (p< 0.0001), at the end of the study period
(week 36). Systolic and diastolic blood pressure showed
a clear reduction after the first two weeks of therapy and
reached the lowest values at week 8. No significant
changes have been detected from week 2 to week 36, as
demonstrated in figure 2. Similar responses of systolic
blood pressure to therapy were observed in the sub-
groups of patients on (n= 122) and off (n= 59) antihy-
pertensive medication. In those on antihypertensive
therapy systolic blood pressure decreased from 144.6 ±
22.0 to 134.9 ± 22.0 mmHg (p< 0.0001) after two
weeks, reaching 133.9 ± 22.1 mmHg at the week 36.
In those not taking antihypertensive drugs systolic
blood pressure decreased from 139.2 ± 12.4 to 134.4 ±
12.7 mmHg (p< 0.0001) after two weeks, reaching
131.6 ± 12.2 mmHg at the end of the study.
For all patients, the distribution of the calcula-
ted Framingham Risk Score (FRS), which is the risk of
coronary heart disease in 10 years (16), before and at
the end of orlistat therapy, is depicted in figure 3. A
beta-density distribution was fitted to the distributions
of the FRS, at weeks 0 and 36, with descriptive pur-
poses. It was observed a clear shift to the left in the
FRS distribution at the end of the study period, when
compared to distribution observed at baseline. These
curves indicate a reduction in the risk of a coronary
event in 10 years, particularly in those patients at high-
er risk categories in the beginning of the study.
Although a small change was observed in the mean of
the calculated FRS for the whole population (from 8.0
± 5.2% to 6.8 ± 4.4%), there was a significant differ-
ence between the risk distribution at weeks 0 and 36
(p= 0.0037). The proportions of patients in the cate-
gories that are considered of intermediate risk (≥ 10%
– < 20%) and high risk (≥ 20%) of a coronary heart dis-
ease in 10 years reduced from 36.4% and 5.8% before
therapy to 19.7% and 3.4%, respectively, by the end of
the study period. In contrast, the proportions of
patients in the low (≥ 5% and < 10%) and very low risk
(< 5%) categories increased from 27.2% to 40.1% and
from 30.6% to 36.7% respectively. Of the 120 patients
in the low, intermediate and high-risk classes, 49.2%
moved to a lower risk category, 45.0% remained in the
same category and only 5.8% moved to a higher risk
category. Of the 54 patients in the lower risk catego-
ry, nine (16%) moved to the moderate risk category.
In the whole group, the thickness of subcuta-
neous fat at CT decreased from 3.23 ± 1.04 cm at base-
line to 3.0 ± 0.97 (p< 0.002) at the end of the study
period while the thickness of the visceral fat was reduced
from 7.61 ± 3.39 to 6.52 ± 3.04 cm (p< 002), within
the same period. No significant correlation was found
between changes in abdominal fat and changes in FRS.
Patients were also divided, according to the per-
centage of body weight lost, in three other categories:
< 5%, ≥ 5% – <10% and ≥ 10%. It was observed a
weight loss ≥ 5% in 64.6% of all patients studied. Table
2 shows that the changes that occurred in the cardio-
vascular risk factors during orlistat therapy were
dependent on the amount of weight lost. At the end
of the study, patients who lost more then 5% of the
initial body weight showed significant reductions in
waist circumference, systolic blood pressure, fasting
glycemia and, total cholesterol, LDL-cholesterol and
triglycerides.
In all patients, fasting glycemia was lower than
126 mg/dl at baseline. From 151 patients who were
submitted to an oral glucose tolerance test, 98 (64.9%)
Table 1. Demographic and clinical characteristics of the
study population.
Age (years) 48 ± 9.3
Weight (kg) 89,8 ±13.6
Systolic Blood Pressure (mmHg) 143 ±12.2
Diastolic Blood Pressure (mmHg) 91 ± 8.6
Body Mass Index (kg/m) 35.0 ± 4.2
Waist circumference (cm) 108.1 ± 10.1
Fasting Blood Glucose (mg/dl) 102.6 ±13.0
Total cholesterol (mg/dl) 203.0 ± 26.1
HDL-cholesterol (mg/dl) 43.5 ± 9.8
LDL-cholesterol (mg/dl) 124.3 ± 30.7
Triglycerides (mg/dl) 188.2 ± 82.0
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presented a normal glucose tolerance, with blood glu-
cose levels at 120 minutes after glucose load < 140
mg/dl; 36 (23.8%) had impaired glucose tolerance
(blood glucose ≥ 140 mg/dl and < 200 mg/dl) and
17 (11.3%) had diabetes (blood glucose ≥ 200
mg/dl). However, as fasting glucose were lower than
126 mg/dl, all patients were considered non-diabetics
for FRS calculation purpose, once for risk stratification
OGTT has not been indicated.
Compared to those with normal glucose toler-
ance, patients with blood glucose levels ≥ 140 mg/dl
at 120 minutes of OGTT had only higher fasting
blood glucose (108.8 ± 11.6 mg/dl vs. 97.8 ± 12.1
mg/dl; p< 0.05) with similar body mass index, waist
circumference, blood pressure and plasma lipid profile.
At the end of the study period, from 36 patients with
impaired glucose tolerance, 23 (63.9%) showed nor-
mal blood glucose levels, 9 (25%) remained with
impaired glucose tolerance and 4 (11.1%) developed
diabetes, detected only by OGTT. From the 17
patients with diabetes at OGTT at baseline, 6 (35.3%)
showed normal glucose tolerance test at the end of the
study, 9 (52.9%) presented with glucose intolerance
and only 2 (11.7%) remained with diabetes at OGTT
after therapy. Overall, of the 53 patients with abnor-
mal glucose metabolism, 38 (71.7%) improved their
glucose tolerance. From the 98 patients with normal
glucose tolerance test 15 (15.3%) developed glucose
intolerance and one developed diabetes. The Cochran-
Mantel-Haenszel statistics showed that the changes in
patients’ distribution toward classes of better glucose
tolerance were significant (p< 0.0005). There was also
an association (chi-square) between decrease in body
weight ≥ 5% and improvement in glucose tolerance
(p< 0.001).
DISCUSSION
Modest weight loss of 5–10% body weight has been
shown to improve insulin sensitivity and other cardio-
vascular risk factors across a wide range of patient
groups (17-20). However, maintenance of the weight
losses, which is difficult to achieve with usual weight
management programs (21), is required for sustained
improvements in coronary heart disease risk factors.
Initial studies with orlistat have indicated that this
treatment is effective and well tolerated and provide
long-term benefits in the management of weight loss
in obese individuals (22-24). This was confirmed in
our study, which demonstrates that such health bene-
fits can be achieved in an obese population with
uncontrolled hypertension and other features of the
metabolic syndrome. The significant decrease in body
weight observed throughout the 16 weeks of treat-
ment was maintained up to 36 weeks of therapy. Fur-
thermore, 64.6% of all patients on orlistat therapy
could maintain more than 5% body weight reduction
Figure 1. (A) Body weight. (B) Waist circumference reductions during a 36-week orlistat plus diet therapy (mean ± SE).
Body weight
(kg)
Waist
circumference
(cm)
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up to the end of the study period. This finding is
important as the potential benefits to the obese indi-
vidual increase the longer the weight reduction can be
maintained (7).
Central adiposity is a well-known cardiovascular
risk factor (25). Several studies have shown that
changes in waist circumference correlate well with
changes in visceral adipose tissue and thus with
changes in risk factors (4,5,26). In this study, the
marked 7% and 10% reduction in waist circumference
in the two groups of patients, which lost 5% and 10%
of the initial body weight, respectively, indicates that
orlistat-related weight loss is accompanied by a
decrease in visceral fat.
The reduction in body weight with orlistat in
our patients resulted in a significant reduction in the
Framingham Risk Score (FRS), with 49.2% patients in
the low, intermediate and high-risk categories moving
to a lower risk category. Since patients included in this
study were not smokers or had overt diabetes, the only
two variables that could have changed the FRS were
total cholesterol and blood pressure, once HDL-cho-
lesterol did not show significant alterations and glu-
cose tolerance is not considered in FRS calculation.
The most pronounced reductions in blood
pressure occurred very early in the study, during the
first two weeks of therapy, associated with a mean
small change in body weight. Also a mean reduction
near 5% was observed in systolic blood pressure even
in the group of patients showing a body weight
reduction less than 5%. A better adherence to anti-
hypertensive medication could be the reason for the
prompt response of blood pressure to therapy. How-
ever, a significant early fall in blood pressure was also
observed in patients who were not on antihyperten-
sive therapy. Considering that no changes in antihy-
pertensive medication were performed throughout
the study period, these observations raise the
hypothesis that not all changes in blood pressure can
be attributed exclusively to weight loss. Changes in
dietary components and/or in other metabolic fac-
tors, occurring with the initial weight loss, may be
contributors to the early improvements observed in
blood pressure (27), although the degree of blood
pressure reduction is marked influenced by the
degree of weight reduction.
The occurrence of insulin resistance in the
metabolic syndrome increases the risk of developing
impaired glucose tolerance and type 2 diabetes.
Besides being a risk factor for the progression to type
2 diabetes, impaired glucose tolerance, defined by
abnormal values of blood glucose concentrations 2
hours after an oral glucose load, is also considered an
independent risk factor for cardiovascular disease. A
metaregression analysis of 20 studies concluded that
nondiabetic degrees of fasting and postprandial
hyperglycemia were associated with cardiovascular
disease (28). Thus, the decrease in 2-hour plasma
glucose indicates not only a reduced diabetes risk but
also a lower risk for cardiovascular disease. A number
of studies (6,29) show that the risk of developing
type 2 diabetes is closely linked to the presence and
duration of overweight and obesity. In contrast,
reduction in the incidence of type 2 diabetes with
lifestyle changes has previously been demonstrated.
The Finnish Diabetes Prevention Study (DPS) and
Figure 2. Systolic and diastolic blood pressure reduction dur-
ing a 36-week orlistat plus diet therapy.
Figure 3. Beta density distribution fitted to the distributions of
the FRS, before (week 0) and after 36 weeks of orlistat plus
diet therapy (week 36).
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the Diabetes Prevention Program (DPP) have shown
that modest weight loss achieved by lifestyle changes
(diet and exercise) can significantly reduce the risk of
developing type 2 diabetes in obese patients with
impaired glucose tolerance (IGT) (30,31). The ben-
efits of adding orlistat to life style changes were pre-
viously demonstrated in the XENDOS Study (32). In
a 4-year, double-blind, prospective study, 3,305
obese patients with normal or impaired glucose tol-
erance were randomized to lifestyle changes plus
either orlistat 120 mg or placebo, three times daily.
Compared with lifestyle changes and placebo, orlistat
plus lifestyle changes for 4 years produced greater
weight loss and reduced by 52% the incidence of type
2 diabetes in subjects with impaired glucose toler-
ance. The present study also showed that orlistat
therapy and a dietary program resulted in a weight
loss greater than 5% in 64.6% of all obese hyperten-
sive patients and improved glucose tolerance in a
subpopulation at higher risk for developing type 2
diabetes. From 53 patients with impaired glucose tol-
erance or diabetes, detected by an oral glucose toler-
ance test, 38 (71.7%) improved their glucose toler-
ance. In contrast, only 15 (15.3%) out 98 patients
with normal glucose tolerance developed impaired
glucose tolerance.
In summary, orlistat treatment resulted in a
high proportion of obese hypertensive patients that
could maintain more than 5% reduction in initial
body weight for 36 weeks. This was associated with
coronary risk reduction and improvement in glucose
metabolism in those with impaired glucose toler-
ance. Thus, dietary modification plus orlistat thera-
py should, therefore, be considered as an option for
the treatment of hypertensive patients with metabol-
ic syndrome. It might help to reduce the need for
multiple drug therapy in these patients, usually
requiring a polypharmacy treatment strategy to
avoid type 2 diabetes and to reduce cardiovascular
risk.
Table 2. Cardiovascular risk factors before and after a 36-week orlistat plus diet therapy in subgroups of patients divided
according to changes in body weight.
Weight Loss Categories
< 5% (n= 64) ≥ 5% – <10% (n= 69) ≥ 10% (n= 48) p**
(35.4%) (38.1%) (26.5%)
Body Mass Index Baseline 35.5 ± 4.5 35.3 ± 4.2 35.2 ± 3.7 ns
(kg/m2) Final 34.9 ± 4.5 32.4 ± 4.0* 30.1 ± 3.3*
∆% -1.7 -8.2 -14.5 0.0001
Waist Baseline 110.1 ±11.7 107.1 ± 9.0 107.4 ± 9.2 ns
circumference (cm) Final 106.0 ±11.7 99.0 ± 9.4* 95.7 ± 9.2*
∆% -3.7 -7.6 -10.9 0.0002
Systolic Blood Baseline 141.8 ± 12.0 143.0 ± 13.3 143.0 ± 10.9 ns
Pressure (mmHg) Final 134.9 ± 14.5* 132.4 ± 19.4* 128.9 ± 14.3*
∆% -4.9 -7.4 -9.8 0.03
Diastolic Blood Baseline 90.3 ± 8.4 91.3 ± 9.5 91.3 ± 7.5 ns
Pressure (mmHg) Final 87.8 ± 8.6 86.2 ± 10.8* 85.0 ± 10.4*
∆% -2.8 -5.6 -6.9 ns
Fasting Blood Baseline 100.4 ± 14.8 104.0 ± 12.1 103.4 ± 11.7 ns
Glucose (mg/dl) Final 102.0 ± 26.1 95.3 ± 13.1* 90.4 ± 13.0*
∆% 2.5 -7.5 -11.5 0.017
Total Cholesterol Baseline 204.7 ± 28.7 202.0 ± 23.4 202.3 ± 26.4 ns
(mmHg) Final 199.7 ± 34.1 184.2 ± 31.3* 182.9 ± 34.9*
∆% -1.9 -8.5 -10.1 0.0007
HDL-cholesterol Baseline 42.8 ± 8.7 43.4 ± 8.4 44.7 ± 12.6 ns
(mmHg) Final 42.4 ± 9.2 44.7 ± 8.3 44.7 ± 11.7
∆% 1.8 4.7 4.0 ns
LDL-cholesterol Baseline 125.3 ± 34.8 121.5 ± 27.0 124.7 ± 31.2 ns
(mmHg) Final 121.0 ± 32.4 109.8 ± 29.0* 111.3 ± 32.6*
∆% 0.1 -9.0 -8.9 ns
Triglycerides Baseline 202.7 ± 77.2 182.2 ± 79.6 177.4 ± 90.3
(mg/dl) Final 186.5 ± 95.8 153.9 ± 63.1* 136.5 ± 74.7*
∆% -2.7 -9.7 -13.3 ns
* p< 0.05 vs. baseline; **comparisons between groups.
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